Compare PRAX & SNEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRAX | SNEX |
|---|---|---|
| Founded | 2015 | 1924 |
| Country | United States | United States |
| Employees | N/A | 5400 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.4B |
| IPO Year | 2020 | 1996 |
| Metric | PRAX | SNEX |
|---|---|---|
| Price | $259.15 | $56.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 3 |
| Target Price | ★ $650.00 | $133.28 |
| AVG Volume (30 Days) | 498.9K | ★ 945.0K |
| Earning Date | 11-04-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 3.49 |
| Revenue | N/A | ★ $132,378,200,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $39,256.17 | N/A |
| P/E Ratio | ★ N/A | $16.39 |
| Revenue Growth | N/A | ★ 32.53 |
| 52 Week Low | $154.46 | $56.46 |
| 52 Week High | $392.70 | $141.99 |
| Indicator | PRAX | SNEX |
|---|---|---|
| Relative Strength Index (RSI) | 38.80 | 26.51 |
| Support Level | $238.77 | N/A |
| Resistance Level | $356.02 | $71.09 |
| Average True Range (ATR) | 12.63 | 2.09 |
| MACD | -0.52 | -0.52 |
| Stochastic Oscillator | 35.55 | 1.18 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
StoneX Group Inc is a brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.